| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1953) |
| Entry Type: | Small molecule |
| Molecule Category: | Salt |
| UNII: | FD171B778Y |
| Parent Compound: | HYDRALAZINE |
| InChI Key | ZUXNZUWOTSUBMN-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C8H9ClN4 |
| Molecular Weight | 196.64 |
| AlogP | 0.92 |
| Hydrogen Bond Acceptor | 4.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 1.0 |
| Polar Surface Area | 63.83 |
| Molecular species | BASE |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 12.0 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Hydrolase
|
- | - | - | 1900-5012 | - | |
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 1
Nuclear hormone receptor subfamily 1 group I
Nuclear hormone receptor subfamily 1 group I member 2
|
450 | - | - | - | - | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 115 |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Alzheimer Disease | 3 | D000544 | ClinicalTrials |
| Heart Failure | 2 | D006333 | ClinicalTrials |
| Cerebral Hemorrhage | 2 | D002543 | ClinicalTrials |
| Macular Degeneration | 2 | D008268 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEBI | 31672 |
| ChEMBL | CHEMBL542541 |
| EPA CompTox | DTXSID1044645 |
| FDA SRS | FD171B778Y |
| PubChem | 9351 |
| SureChEMBL | SCHEMBL36271 |